3647 results for «686»
3647 results
TAVI in small annulus and coronary artery disease - Session with LIVE case
19 Feb 2023 – From PCR Tokyo Valves 2023
Watch the complex case of an 84-year-old woman with hypertension, type 2 diabetes and coronary artery disease who presented with worsening NYHA class II-III exertional dyspnoea, but no angina, and find out how she was treated LIVE.
The optimal first valve choice for all patients with aortic stenosis
18 Feb 2023 – From PCR Tokyo Valves 2023
How have advances in TAVI impacted the lifetime journey of patients with aortic stenosis? Join this panel of experts as they discuss the importance of optimizing the first procedure and the key issues regarding treatment options in patients with bioprosthetic valve deterioration of transcatheter heart valve.
How to optimise the lifetime management of TAVI patients with long-life expectancy?
18 Feb 2023 – From PCR Tokyo Valves 2023
This session addresses three essential elements of a successful TAVI procedure: the impact of valve design on long-term durability, how to mitigate the risk of paravalvular leakage, and the importance of the possibility for coronary access after TAVI.
Remaining unmet needs and strategies in TAVI
19 Feb 2023 – From PCR Tokyo Valves 2023
This session focuses on valve design and durability performance in TAVI for patients with aortic stenosis, and the way it impacts future patient outcomes.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...
Author
